z-logo
Premium
Microwave Synthesis of Coumarinyl Substituted Pyridine Derivatives as Potent Anticancer Agents and Molecular Docking Studies
Author(s) -
Chougala Bahubali M.,
S Samundeeswari,
Holiyachi Megharaja,
Naik Nirmala S.,
Shastri Lokesh A.,
Dodamani Suneel,
Jalalpure Sunil,
Dixit Sheshagiri R,
Joshi Shrinivas D.,
Sunagar Vinay A
Publication year - 2017
Publication title -
chemistryselect
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.437
H-Index - 34
ISSN - 2365-6549
DOI - 10.1002/slct.201700358
Subject(s) - malononitrile , chemistry , ammonium acetate , podophyllotoxin , docking (animal) , pyridine , stereochemistry , tubulin , molecular model , molecule , combinatorial chemistry , protein data bank (rcsb pdb) , hydrazone , catalysis , biochemistry , medicinal chemistry , organic chemistry , microtubule , biology , medicine , high performance liquid chromatography , nursing , microbiology and biotechnology
Catalyst free new bioactive 2‐amino‐4‐(2‐oxo‐2H‐chromen‐4‐yl)‐6‐arylpyridine‐3‐carbonitrile molecular entities ( 2 a‐2 o ) have been synthesized from 4‐formylcoumarins with malononitrile, different ketones and ammonium acetate via one‐pot four component coupling reaction under neat microwave method. Detailed characterization of all the compounds and anticancer properties for the synthesized compounds are reported. Compounds 2 f and 2 k exhibited promising anticancer activity at low concentration (10 −5 M) against NCI‐60 cell lines. Further, IC 50 values were calculated for most potent compounds against three cancer cell lines such as HT‐29, Hep‐G2 and KB. Among the eight compounds, 2 f and 2 k are exhibited most promising activity, the potent anticancer molecules 2 f and 2 k were screened for their CT‐DNA cleavage and fluorescence quenching study with transport protein BSA. Molecular docking study has been performed for the synthesized compounds with binding site of the tubulin using podophyllotoxin‐tubulin stathmin‐like domain complex (PDB 1SA1) and results obtained are quite good.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here